宫颈癌根治性放疗中不同大小淋巴结是否应推荐个体化剂量提升
本研究纳入2013年9月至2016年12月接受根治性放疗的1002例FIGO 2009分期IB1-IVA期宫颈癌患者,按治疗前CT/MRI所示淋巴结短径分为<1 cm、1-2 cm和≥2 cm三组。结果显示<1 cm淋巴结无需剂量提升,1-2 cm淋巴结剂量≥55 Gy较<55 Gy可提高淋巴结控制率和5年无进展生存率,但5年总生存率无显著差异;≥2 cm淋巴结剂量≥55 Gy组各项指标虽较高但均未达统计学显著。
要点
- <1 cm淋巴结不同剂量组(≤50.4 Gy、50.4-60 Gy、>60 Gy)的淋巴结控制率、5年OS和5年PFS均无显著差异。
- 1-2 cm淋巴结剂量≥55 Gy组较<55 Gy组淋巴结控制率(98% vs 93.6%,P=0.028)和5年PFS(69.6% vs 56.7%,P=0.025)显著更高,5年OS无显著差异(72.6% vs 68.3%,P=0.5)。
- ≥2 cm淋巴结剂量≥55 Gy组较<55 Gy组淋巴结控制率、5年OS和5年PFS均无显著差异(P=0.107、P=0.141、P=0.232)。
核心结论
- 作者结论认为<1 cm淋巴结不需要剂量提升,1-2 cm淋巴结剂量提升至55 Gy已足够。
研究设计与样本
- 本研究为纳入1002例FIGO 2009分期IB1-IVA期宫颈癌患者的研究,患者于2013年9月至2016年12月接受根治性放疗。
- 所有经CT/MRI识别的淋巴结按治疗前短径分为<1 cm、1-2 cm和≥2 cm三组。
主要发现
- 共580例患者检出1310枚淋巴结,<1 cm、1-2 cm和≥2 cm组的淋巴结控制率分别为99.4%、96%和75.9%(P=0.000)。
- <1 cm淋巴结中,≤50.4 Gy、50.4-60 Gy和>60 Gy三组的淋巴结控制率分别为99.4%、99.3%和100%(P=0.647),5年OS分别为76.2%、79%和81.6%(P=0.682),5年PFS分别为74.1%、73.9%和78.9%(P=0.713)。
- 1-2 cm淋巴结中,剂量≥55 Gy组较<55 Gy组淋巴结控制率分别为98%和93.6%(P=0.028),5年PFS分别为69.6%和56.7%(P=0.025),5年OS分别为72.6%和68.3%(P=0.5)。
- ≥2 cm淋巴结中,剂量≥55 Gy组较<55 Gy组淋巴结控制率分别为82.1%和63.2%(P=0.107),5年OS分别为60.6%和37.5%(P=0.141),5年PFS分别为51.5%和37.5%(P=0.232)。
关键数值与推荐
- <1 cm淋巴结:≤50.4 Gy、50.4-60 Gy、>60 Gy三组的淋巴结控制率、5年OS和5年PFS均无显著差异。
- 1-2 cm淋巴结:剂量≥55 Gy组较<55 Gy组淋巴结控制率和5年PFS显著更高,5年OS无显著差异。
- ≥2 cm淋巴结:剂量≥55 Gy组较<55 Gy组淋巴结控制率、5年OS和5年PFS均无显著差异。
临床怎么用
- 作者结论认为<1 cm淋巴结不需要剂量提升,1-2 cm淋巴结剂量提升至55 Gy已足够。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Dose escalation for positive node maybe improve the regional control of patients with node-positive cervical cancer, but the optimal dose for nodes of different sizes remains controversial. The purpose of this study was to explore the individualized dose escalation for lymph nodes (LNs) with different sizes in the definitive radiotherapy of cervical cancer. METHODS: A total of 1002 cervical cancer patients with the International Federation of Gynecology and Obstetrics (FIGO 2009) stage IB1-IVA, who were treated by definitively radiotherapy between September 2013 and December 2016 were enrolled. All LNs identified by computed tomography/magnetic resonance imaging (CT/MRI) were assigned into three groups according to the short diameters of < 1 cm, 1-2 cm or ≥ 2 cm at pretreatment. RESULTS: In total, 580 patients with 1310 LNs were detected. The nodal control rate in groups of LNs < 1 cm, 1-2 cm and ≥ 2 cm was 99.4%, 96%, and 75.9%, respectively (P = 0.000). Among LNs < 1 cm, the control, overall survival (OS) and progression-free survival (PFS) rates did not significantly differ among three dose-based groups (≤ 50.4 Gy, 50.4-60 Gy, > 60 Gy) (control rate, 99.4% vs. 99.3% vs. 100%, P = 0.647) (5-year OS, 76.2% vs. 79% vs. 81.6%, P = 0.682) (5-year PFS, 74.1% vs. 73.9% vs. 78.9% P = 0.713). Among LNs of 1-2 cm, the control and PFS rates were significantly higher in the group of dose ≥ 55 Gy than the group of dose < 55 Gy (control rate, 98% vs. 93.6%, P = 0.028) (5-year PFS, 69.6% vs. 56.7%, P = 0.025). However, this did not cause a significant difference for 5-year OS rate (72.6% vs. 68.3%, P = 0.5). Among LNs ≥ 2 cm, the control, OS, and PFS rates were higher in the group of dose ≥ 55 Gy than the group of dose < 55 Gy, while no significant difference was found (control rate, 82.1% vs. 63.2%, P = 0.107) (5-year OS, 60.6% vs. 37.5%, P = 0.141) (5-year PFS, 51.5% vs.37.5%, P = 0.232). CONCLUSIONS: Radiation dose escalation is not necessary for LNs < 1 cm, and dose escalation of 55 Gy is enough for LNs of 1-2 cm.
引用
- Lv X, Rao H, Feng T, et al. Whether individualized dose escalation should be recommended for lymph nodes with different sizes in the definitive radiotherapy of cervical cancer? Radiat Oncol. 2022. PMID: 36266716. doi:10.1186/s13014-022-02132-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。